Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.

AIMS Cyclic GMP (cGMP)-specific phosphodiesterase 5 (PDE5) inhibition by sildenafil (SIL) activates myocardial cGMP-dependent protein kinase G (PKG) and blunts cardiac hypertrophy. To date, the only documented target of PKG in myocardium is the serine-threonine phosphatase calcineurin (Cn), which is central to pathological cardiac hypertrophy. We tested whether Cn suppression is necessary in order to observe anti-hypertrophic effects of SIL. METHODS AND RESULTS Mice lacking the Cn-Abeta subunit (CnAbeta(-/-)) and wild-type (WT) controls were subjected to transverse aorta constriction (TAC) with or without SIL (200 mg/kg/day, p.o.) for 3 weeks. TAC-induced elevation of Cn expression and activity in WT was absent in CnAbeta(-/-) hearts, and the latter accordingly developed less cardiac hypertrophy (50 vs. 100% increase in heart weight/tibia length, P < 0.03) and chamber dilation. SIL remained effective in CnAbeta(-/-) mice, increasing PKG activity similarly as in WT, suppressing hypertrophy and fetal gene expression, and enhancing heart function without altering afterload. TAC-stimulated calcium-calmodulin kinase II, Akt, and glycogen synthase kinase 3beta in both groups (the first rising more in CnAbeta(-/-) hearts), and SIL also suppressed these similarly. Activation of extracellular signal-regulated kinase observed in WT-TAC but not CnAbeta(-/-) hearts was also suppressed by SIL. CONCLUSION PDE5A inhibition and its accompanying PKG activation blunt hypertrophy and improve heart function even without Cn activation. This occurs by its modulation of several alternative pathways which may result from concomitant distal targeting, or activity against a common proximal node.

[1]  Yuejin Wu,et al.  Death, Cardiac Dysfunction, and Arrhythmias Are Increased by Calmodulin Kinase II in Calcineurin Cardiomyopathy , 2006, Circulation.

[2]  J. Molkentin,et al.  Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.

[3]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[4]  Rick B. Vega,et al.  Control of Cardiac Growth and Function by Calcineurin Signaling* , 2003, Journal of Biological Chemistry.

[5]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[6]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[7]  M. Curran,et al.  Sildenafil: a review of its use in pulmonary arterial hypertension. , 2008, Drugs.

[8]  E. Olson,et al.  CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. , 2006, The Journal of clinical investigation.

[9]  D. Castrillon,et al.  Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling , 2006, Circulation.

[10]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[11]  L. Ruilope,et al.  Left ventricular hypertrophy and clinical outcomes in hypertensive patients. , 2008, American journal of hypertension.

[12]  J. Molkentin,et al.  Impaired cardiac hypertrophic response in Calcineurin Aβ-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Nelson,et al.  Functional coupling of calcineurin and protein kinase A in mouse ventricular myocytes , 2002, The Journal of physiology.

[14]  Tong Zhang,et al.  The Cardiac-specific Nuclear δB Isoform of Ca2+/Calmodulin-dependent Protein Kinase II Induces Hypertrophy and Dilated Cardiomyopathy Associated with Increased Protein Phosphatase 2A Activity* , 2002, The Journal of Biological Chemistry.

[15]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[16]  H. Itoh,et al.  cGMP-dependent protein kinase phosphorylates and inactivates RhoA. , 2001, Biochemical and biophysical research communications.

[17]  Rick B. Vega,et al.  Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Molkentin,et al.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle* , 2000, The Journal of Biological Chemistry.

[20]  R. Kloner,et al.  Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. , 2003, Circulation.

[21]  M. Hendriks-Balk,et al.  Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. , 2008, European journal of pharmacology.

[22]  Chao-Yung Wang,et al.  Decreased Perivascular Fibrosis but Not Cardiac Hypertrophy in ROCK1+/− Haploinsufficient Mice , 2005, Circulation.

[23]  Rick B. Vega,et al.  Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  David M. Harris,et al.  Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat. , 2007, American journal of physiology. Heart and circulatory physiology.

[25]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[26]  Donald M Bers,et al.  Role of Ca2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. , 2007, Cardiovascular research.

[27]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[28]  J. Molkentin,et al.  Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart , 2000, The Journal of Biological Chemistry.

[29]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[30]  H. Drexler,et al.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Kass,et al.  Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.

[32]  IsseiKomuro,et al.  Isoproterenol Activates Extracellular Signal–Regulated Protein Kinases in Cardiomyocytes Through Calcineurin , 2001 .

[33]  K. Nakao,et al.  Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart , 2008, Circulation.

[34]  E. Olson,et al.  Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Gamidov,et al.  The effect of vardenafil on endothelial function of brachial and cavernous arteries , 2006, International journal of impotence research.

[36]  J. Corbin,et al.  Sildenafil citrate does not affect cardiac contractility in human or dog heart , 2003, Current medical research and opinion.

[37]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[38]  H. Champion,et al.  Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension , 2006, Expert review of cardiovascular therapy.

[39]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[40]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[41]  E. Olson,et al.  Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Pál Pacher,et al.  Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats , 2008, Nature Protocols.

[43]  E. Olson,et al.  Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Olson,et al.  Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress , 2004, Nature Medicine.

[45]  T. McKinsey.  Derepression of pathological cardiac genes by members of the CaM kinase superfamily. , 2007, Cardiovascular research.

[46]  P. Doevendans,et al.  Calcineurin and hypertrophic heart disease: novel insights and remaining questions. , 2002, Cardiovascular research.

[47]  J. Molkentin,et al.  Direct and Indirect Interactions between Calcineurin-NFAT and MEK1-Extracellular Signal-Regulated Kinase 1/2 Signaling Pathways Regulate Cardiac Gene Expression and Cellular Growth , 2005, Molecular and Cellular Biology.

[48]  H. Padma-nathan,et al.  Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness , 2006, International Journal of Impotence Research.

[49]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[50]  K. Nakao,et al.  Calcineurin–Nuclear Factor of Activated T Cells Pathway–Dependent Cardiac Remodeling in Mice Deficient in Guanylyl Cyclase A, a Receptor for Atrial and Brain Natriuretic Peptides , 2005, Circulation.

[51]  D. Kass,et al.  Phosphodiesterase regulation of nitric oxide signaling. , 2007, Cardiovascular research.